MergerJun 9, 2026, 07:11 AM
GSK to Acquire Nuvalent for $10.6 Billion
AI Summary
GSK plc has entered into an agreement to acquire Nuvalent, Inc. for $10.6 billion. The acquisition includes Nuvalent's portfolio of oncology assets, notably two late-stage inhibitors for non-small cell lung cancer (NSCLC): zidesamtinib (ROS1) and neladalkib (ALK). The deal, valued at $124 per share in cash, represents a significant premium and is expected to accelerate GSK's entry into the lung cancer market. The acquisition is projected to be accretive to GSK's financial performance starting in 2027 and is anticipated to close in the third quarter of 2026, subject to regulatory approvals.
Key Highlights
- GSK plc to acquire Nuvalent, Inc. for $10.6 billion in cash.
- The acquisition includes two late-stage oncology assets: zidesamtinib (ROS1 inhibitor) and neladalkib (ALK inhibitor) for NSCLC.
- The deal is expected to be accretive to GSK's sales and core operating profit in 2027 and core EPS in 2029.
- Nuvalent's shares to be acquired at $124 per share, representing a 40% premium to the last closing price.
- The transaction is subject to customary closing conditions, including regulatory approvals.
- GSK expects the acquisition to close in Q3 2026.
Price Impact
More from NUVL